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Epidemiologic studies have shown that the consumption of green
tea lowers the risk of developing gastric and colon cancers (Yu et al,
1995; Ji et al, 1997). In rodent models, green tea preparations
protect against the development of skin, lung, mammary gland and
gastrointestinal tract cancers (Rogers et al, 1998). The anticarcino-
genic and antiproliferative effects of green tea have been attributed
to the biological activities of its polyphenol components. 
Green tea extract contains (-)-epigallocatechin gallate (EGCG), 
(-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG), and (-)-
epicatechin (EC) (Stoner and Mukhtar, 1995). EGCG, the most
abundant polyphenol in green tea, has been shown to inhibit cell
proliferation (Asano et al, 1997) and induce apoptosis (Hibasami
et al, 1998; Paschka et al, 1998) in tumour cells. Other means by
which EGCG may prevent cancer include its inhibition of uro-
kinase activity (Jankun et al, 1997), mitogen-activated protein
kinases (MAPKs) activation (Jankun et al, 1997; Ahn et al, 1999),
lipooxygenase and cyclooxygenase activities (Stoner and
Mukhtar, 1995), and arrest of the cell cycle (Ahmad et al, 1997;
Fujiki et al, 1998) in tumour cells. 
Signalling pathways that mediate proliferation also mediate
other processes involved in tumour progression (Ellis et al, 1998;
Jung et al, 1999). Tumour growth induced by mitogenic com-
pounds is associated with the activation of several cytosolic
proteins, including those involved in the phosphorylation and activa-
tion of MAPKs (Cobb and Goldsmith, 1995). Among the three
subgroups of MAPKs in mammalian cells, the Erks seem to be the
most important for growth factor-induced cell proliferation (Davis,
1993). Regulators of angiogenesis are also important determinants
of tumour growth (Folkman, 1995) and various signal transduction
pathways have been implicated in regulating angiogenic factor
expression. Vascular endothelial growth factor (VEGF) is the
angiogenic factor most closely associated with inducing and main-
taining the neovasculature in human colon cancer (Takahashi et al,
1995, 1997; Ellis et al, 1996). Activation of Erk-1 and Erk-2 have
been shown to be important mediators for up-regulation of VEGF
mRNA. Milanini et al (1998) demonstrated that activation of Erk-1
and Erk-2 play a key role in the regulation of the VEGF expression
via alteration of AP-2 and Sp1 transcription factors in fibroblasts.
Our previous studies on VEGF induction in serum-starved cells
revealed a causal role for the activation of Erk – but not of P38,
stress-activated protein kinase (SAPK) or Akt (Jung et al, 
1999). 
A recent finding that green tea and one of its components,
EGCG, prevents the growth of new blood vessels in animals (Cao
and Cao, 1999) suggests a mechanistic link between the con-
sumption of tea and the possible prevention and treatment of
angiogenesis-dependent diseases, including cancer. In this study,
we investigated the effects of green tea catechins on VEGF expres-
sion in vitro and their effects on tumour growth in vivo in human
colon cancer xenografts in nude mice. 
MATERIALS AND METHODS 
Reagents 
Purified EGCG, EGC, ECG, and EC were obtained from Sigma
Chemical Co (St Louis). Other reagents were obtained as follows:
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optimum cutting temperature (OCT) compound from Miles Inc
(Elkhart), diaminobenzidine substrate (DAB) and Universal Mount
from Research Genetics (Huntsville), Superfrost slides from Fisher
Scientific Co (Houston), terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick-end labelling (TUNEL) kit from
Promega (Madison), and 4,6-diamidino-2-phenylindole dihydro-
chloride (DAPI) mount from Vector Laboratories Inc (Burlingame). 
Antibodies for the immunohistochemical analyses were
obtained as follows: rat anti-mouse CD31/PECAM-1 antibody
from Pharmingen (San Diego); mouse anti-PCNA clone PC 10
DAKO A/S from Dako Corp (Carpinteria); peroxidase-conjugated
goat anti-rat immunoglobulin (IgG) (H+L) and Texas Red- and
fluorescein-conjugated goat anti-rat IgG from Jackson Research
Laboratories (West Grove); and peroxidase-conjugated rat anti-
mouse IgG2a from Serotec Harlan Bioproducts for Science Inc
(Indianapolis). 
Cell culture 
The human colon cancer cell line HT29 was obtained from the
American Type Culture Collection (Manassas) and cultured in
minimal essential medium (MEM) supplemented with 10% fetal
bovine serum (FBS), 2 U ml–1penicillin and streptomycin, 1 mM
sodium pyruvate, 2 mM L-glutamine, vitamins, and nonessential
amino acids at 37˚C under 5% CO2. Serum deprivation was
induced by excluding FBS from the standard culture medium after
cells had reached 90–100% confluence. 
Western blot hybridization 
Cells were rinsed twice with ice-cold phosphate-buffered saline
(PBS) and then lysed with protein lysis buffer (20 mM Na-
phosphate (pH 7.4), 150 mM NaCl, 1% Triton X-100, 5 mM
EDTA, 5 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 1 mg
ml–1 leupeptin, and 500 mM Na3VO4). Protein levels were quanti-
fied spectrophotometrically, and 100-mg portions were subjected
to electrophoresis on 8% polyacrylamide gels, transferred to nitro-
cellulose membranes (Schleicher & Schuell, Keene) by electro-
transfer, blocked with 5% milk in PBS-T (0.5% Tween 20 in PBS),
and probed with the primary antibody (1:1000 dilution of rabbit
anti-phosphospecific p44/42 MAPK antiserum for phosphorylated
Erk-1 and -2 (New England Biolabs Inc, Beverly). 
The membranes were then washed and treated with secondary
antibody labelled with horseradish peroxidase (anti-rabbit
immunoglobulin antiserum from donkey at a 1:3000 dilution,
Amersham, Arlington Heights). Protein bands were visualized with
a commercially available chemoluminescence kit (Amersham).
To quantify total Erk-1 and -2 protein levels, the membrane was
washed with stripping solution (100 mM 2-mercaptoethanol, 2%
SDS, and 62.5 mM Tris-HCl (pH 6.7)) for 30 min at 50˚C and
reprobed with rabbit anti-p44/42 MAPK antiserum (New England
Biolabs) at a 1:1000 dilution. 
mRNA extraction and Northern blot analysis 
Total RNA was extracted from cells by using the Tri Reagent
(Molecular Research Center Inc, Cincinnati). Northern blot
hybridization was performed as previously described (Jung et al,
1999). In brief, total RNA (25 mg) was subjected to electrophoresis
on 1% denaturing formaldehyde-agarose gels, transferred to a
Hybond-N+ positively charged nylon membrane (Amersham)
overnight by capillary elution, and ultraviolet cross-linked at 
120 000 mJc m –2 by using an ultraviolet Stratalinker 1800
(Stratagene, La Jolla). The blots were prehybridized for 3–4 h at
65˚C in rapid hybridization buffer (Amersham), and the
membranes were hybridized overnight at 65˚C with the cDNA
probe for VEGF or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (see below). The probed nylon membranes were then
washed and exposed to radiographic film (GIBCO BRL Life
Technologies Inc, Grand Island). 
A human VEGF-specific 204-bp cDNA probe was a gift from
Dr Brygida Berse (Harvard Medical School, Boston), and a
GAPDH probe was purchased from the American Type Culture
Collection (Manassas). The VEGF probe identifies all of the alterna-
tively spliced forms of VEGF mRNA transcripts. Probes were
purified by agarose gel electrophoresis by using the QIAEX Gel
Extraction kit (QIAGEN Inc, Chatworth). Each cDNA probe was
radiolabeled with (a-32P) deoxyribonucleotide triphosphate by
using the random-priming technique with the Rediprime labeling
system (Amersham). 
VEGF promoter-reporter activity in response to serum
starvation 
The effect of EGCG on the transcriptional regulation of VEGF by
serum starvation of HT29 cells was examined by using transient
transfection with a VEGF promoter (luciferase)-reporter con-
struct. Full-length VEGF promoter cDNA, kindly provided by
J Abraham (Scios Nova Inc, Mountain View), was subcloned
into pGL3 by using standard techniques (Akagi et al, 1998). The
following plasmids were used: pGL3-VEGF (containing the
human VEGF promoter linked to the firefly luciferase reporter
gene) (Promega, Madison), pRLTK (an internal control plasmid
containing the herpes simplex thymidine kinase promoter linked to
a constitutively active Renilla luciferase reporter gene), and
pGL3 (plasmid vector alone as a negative control). HT29 cells
(0.5–1.0 ´ 106) were seeded in 6-well plates, and the pRLTK and
pGL3-VEGF constructs were cotransfected into cells with the
FuGENETM6 Transfection Reagent (Boehringer Mannheim,
Indianapolis) as described by the manufacturer. pRLTK and pGL3
were cotransfected as a negative control. 
After cells were incubated in the transfection medium for 24 h,
the medium was changed to standard medium and the cells were
incubated for another 24 h, after which they were incubated in
serum-free medium for 24 h. To determine whether EGCG could
inhibit the increase in VEGF-promoter activity associated with
serum deprivation, cells were treated with EGCG 1 h before being
exposed to the serum-free condition. Cells were harvested with
passive lysis buffer (Dual-Luciferase Reporter Assay System,
Promega), and luciferase activity was determined with a single-
sample luminometer, as outlined in the manufacturer’s protocol. 
Tumour cell inoculation and EGCG treatment 
Six-week-old male athymic BALB/c nude mice were obtained
from the National Cancer Institute’s Animal Production Area
(Frederick) and were acclimated for 1 week. Mice were then
injected subcutaneously with 106 viable HT29 cells. Beginning
2 days later, mice were given daily intraperitoneal injections of
1.5 mg EGCG or EC (control). (Our previous studies have shown
no difference between mice injected with EC and those injected846 YD Jung et al 
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with PBS (data not shown), so we elected to use EC as the control
condition.) Animals were observed daily for tumour growth, and
when tumours appeared they were measured every 3 days. Tumour
volume was calculated as 0.5 ´ length ´ width2 (length > width).
All animal studies were conducted in accord with institutional
guidelines approved by the Animal Care and Use Committee of
The University of Texas MD Anderson Cancer Center. 
Necropsy and tissue preparation 
Mice were killed by cervical dislocation 22 days after tumour-cell
implantation. The tumours were excised, weighed, and sectioned
and the tumour sections were either embedded in OCT compound
and frozen at –70˚C or fixed in formalin. 
Immunohistochemical analysis 
Tumour vessel formation was assessed immunohistochemically
by staining the tumour sections for CD31 and proliferating cell
nuclear antigen (PCNA) as follows. Formalin-fixed or paraffin-
embedded sections were treated by standard deparaffinization, and
sections frozen in OCT were treated by fixation in acetone and
chloroform; immunohistochemical analyses then were performed
as described elsewhere (Shaheen et al, 1999). Briefly, endogenous
peroxidases were blocked with 3% H2O2 in methanol, slides were
washed in PBS, incubated for 20 min with protein-blocking
solution (PBS supplemented with 1% normal goat serum and 5%
normal horse serum), incubated overnight at 4˚C with primary
antibodies directed against CD31 or PCNA. Then the slides were
washed again, incubated with protein-blocking solution, incubated
for 1 h at room temperature with peroxidase-conjugated secondary
antibodies, washed, incubated with DAB, washed, counterstained
with haematoxylin, washed, mounted with Universal Mount, and
dried on a 56˚C hot-plate. Negative controls were prepared with
the same procedure but without the primary antibody. 
Immunofluorescent staining for CD31 and the TUNEL
assay 
Frozen tumour sections were stained by immunofluorescence for
CD31 according to the above protocol with the following modi-
fications. After sections were incubated overnight at 4˚C with the
primary antibody, washed, and incubated with protein-blocking
solution, they were incubated for 1 h at room temperature with a
secondary antibody that was conjugated to Texas Red (red fluores-
cence), washed, and then TUNEL staining was performed
according to the manufacturer’s protocol. Briefly, the sections
were fixed with 4% methanol-free paraformaldehyde, washed,
permeabilized with 0.2% Triton X-100, washed, incubated with
the kit’s equilibration buffer, incubated with a reaction mix
containing equilibration buffer, nucleotide mix, and the TdT
enzyme at 37˚C for 1 h, incubated for 15 min at room temperature
with 2 ´ standard saline citrate to stop the TdT reaction, washed,
stained with DAPI mount (to visualize the nuclei), and glass cover-
slips were applied. 
Quantification of CD31, PCNA and TUNEL 
Tumour vessels and PCNA-positive cells were evaluated by light
microcopy, counted in five random 0.159-mm2 fields at 100 ´
magnification, imaged digitally, and processed with Optimas
Image Analysis software (Biscan, Edmond). We also quantified
apoptosis with immunofluorescence by imaging sections digitally
and processing them with Adobe Photoshop software (Adobe
Systems, Mountain View). CD31-positive endothelial cells were
detected by localized red fluorescence using a rhodamine filter.
Tumour and endothelial cell apoptosis was visualized by localized
green fluorescence using a fluorescein filter. Nuclei were detected
by blue fluorescence of the DAPI with its respective filter. Cell
counts were obtained in five random 0.011-mm2 fields per slide at
400 ´ magnification. The percentage of apoptotic cells was deter-
mined as (number of apoptotic cells / total number of cells) ´ 100). 
Statistical analysis 
Statistical comparisons among groups were made with the
Mann–Whitney U-test for non-parametric data or Student’s t-test
for parametric data (promoter studies) (InStat Statistical Software,
San Diego) at the 95% confidence level (P < 0.05 was considered
statistically significant). 
RESULTS 
Erk-1 and -2 activation 
Erk-1 and Erk-2 were found to be activated (phosphorylated) in
serum-deprived HT29 cells, as previously reported (Jung et al,
1999), whereas the total levels of Erk-1 and Erk-2 did not change
significantly. Our previous studies demonstrated that pretreating
the cells with 1 mg ml–1 of green tea extract inhibited the Erk-1
and -2 activation that had been induced by serum deprivation (data
not shown). Purified EGCG, at 30 mM, markedly inhibited Erk-1
and -2 activation, but EGC, ECG, and EC at this concentration had
no effect (Figure 1A). Next, we treated cells with 0, 10, 30, or
50  mM EGCG under serum-free conditions and found that
EGCG inhibited the Erk-1 and -2 activation in serum-deprived
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Figure 1 EGCG, but not other tea catechins, blocks Erk-1 and -2 activation
induced by serum deprivation. HT29 cells were treated with the indicated
amounts of (-)-epigallocatechin gallate (EGCG), (-)-epigallocatechin (EGC),
(-)-epicatechin gallate (ECG), or (-)-epicatechin (EC) in serum-free media for
9 h, and the cell lysates were analysed for phosphorylated and total forms of
Erk-1 and -2 protein by Western blotting. Only EGCG blocked Erk-1 and -2
activity induced by serum starvation (A), and it did so in a dose-dependent
fashion (B) EGCG inhibits tumour growth and VEGF expression 847
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VEGF expression
Since Erk-1 and -2 activation is known to be involved in the
induction of VEGF by serum deprivation, we next examined the
effect of EGCG on VEGF expression. EGCG inhibited VEGF
expression in serum-deprived HT29 cells in a dose-dependent
manner, but EC did not affect VEGF expression at any dose
(Figure 2). Neither EGC nor ECG (at 50 mM concentrations)
affected VEGF expression in serum-starved cells (data not
shown). 
Transcriptional regulation of VEGF 
To examine the effect of EGCG on the transcriptional regulation of
VEGF induced by serum starvation, we transiently transfected
promoter-reporter constructs into HT29 cells. Cells transfected
with pGL3-VEGF (promoter-reporter construct) and pRLTK
(internal control) demonstrated an increase in VEGF promoter
activity secondary to serum starvation. Treating cells with EGCG
inhibited the activity of the VEGF promoter in a dose-dependent
fashion (Figure 3). 
Growth of HT29 cells in vivo 
Daily injections of EGCG (1.5 mg mouse–1 day–1) produced no signs
of toxicity in athymic mice and effectively suppressed the growth of
HT29 cells that had been implanted subcutaneously into those mice.
At 22 days after tumour-cell implantation, tumour volume was
inhibited by 61% (Figure 4A) and tumour weight was inhibited by
58% (Figure 4B) in the EGCG-treated group. In preliminary studies,
we demonstrated that there was no difference in tumour size
between mice injected with EC and those injected with PBS (data
not shown); therefore we used EC as the control agent. 
Tumour angiogenesis and tumour cell proliferation 
We used immunohistochemical staining for CD31 to reveal vessel
formation in tumour sections. At 22 days after tumour-cell
implantation, daily EGCG treatment had decreased the number





- + + ++++ +++
10 30 50 100 10 30 50 100
(mM)
EC EGCG Control
Figure 2 EGCG inhibits the VEGF expression induced by serum
deprivation. HT29 cells were treated with the indicated amounts of 
(-)-epigallocatechin gallate (EGCG) or (-)-epicatechin (EC) in serum-free
medium for 48 h. Total RNA was isolated and analysed for VEGF and






































Figure 3 EGCG inhibits the induction of VEGF promoter activity in colon
carcinoma cells. HT29 cells were co-transfected with pGL3-VEGF (a VEGF
promoter–luciferase-reporter construct) and pRLTK (control for transfection
efficiency); co-transfection of pGL3 and pRLTK was used as a negative
control. After 23 h, (-)-epigallocatechin gallate (EGCG) was added, and 1 h
thereafter the medium was changed to serum-free medium. Cells were
harvested after 24 h of serum starvation, protein was extracted, and
luciferase activity was determined. Five separate experiments were done and
results were standardized to reporter activity at t = 0 (contro; control values
were set at 1 or 1.1 to allow for statistic analysis utilizing our computer
software program). Bars indicate standard error of the mean.*P < 0.05
(unpaired Student’s T-test) 
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Figure 4 EGCG reduces tumour volume and weight. At 22 days after tumour-cell implanatation, (-)-epigallocatechin gallate (EGCG) had inhibited tumour
volume by 61% (A) and tumour weight by 58% (B) relative to tumours from mice treated with (-)-epicatechin (EC). Bars indicate standard error.*P < 0.05 
(10 mice per group) 848 YD Jung et al 
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(Figure 5A). Tumour cell proliferation was evaluated by immuno-
histochemical staining for PCNA. Tumours from mice treated with
EGCG had significantly less tumour cell proliferation (27%) than
that of controls (Figure 5A). 
Apoptosis of tumour and endothelial cells 
Immunofluorescent TUNEL staining with concurrent staining for
CD31 was performed to quantify endothelial apoptosis in tumour
sections (Shaheen et al, 1999). EGCG treatment produced a 1.9-fold
increase in tumour cell apoptosis and a 3-fold increase in endothelial
cell apoptosis, compared with those of controls (Figure 5B). The
differences in microvessel density, tumour cell proliferation and
endothelial cell apoptosis between the EC and EGCG groups are
illustrated in Figure 6. 
DISCUSSION 
EGCG is the most abundant of the green tea polyphenols,
accounting for more than 40% of the total polyphenolic mixture
(Stoner and Mukhtar, 1995). Several molecular mechanisms have
been suggested for EGCG’s observed anticancer effect, including
suppression of ligand binding to the EGF receptor (Liang et al,
1997); inhibition of urokinase (Jankun et al, 1997), protein kinase C
(Kitano et al, 1997), lipoxygenase, and cyclooxygenase activities
(Stoner and Mukhtar, 1995); and induction of apoptotic cell death
and arrest of the cell cycle (Ahmad et al, 1997; Fujiki et al, 1998)
in tumour cells. 
In the present study, we found that EGCG inhibited angiogen-
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Figure 5 EGCG inhibits tumour vascularity and tumour cell proliferation. Immunohistochemical staining of tumour sections for CD31 and proliferating cell
nuclear antigen (PCNA) was used to quantify tumour vessels and tumour cell proliferation. A (-)-epigallocatechin gallate (EGCG) inhibited tumour vascularity by
30% and tumour cell proliferation by 27%. B Immunofluorescent double staining of tumour sections for CD31 and TdT-mediated dUTP nick-end labelling
(TUNEL) was performed to quantify the percentages of tumour and endothelial cells undergoing apoptosis. EGCG treatment significantly increased apoptosis of




























Figure 6 Appearance of human colon cancer xenograft sections in 
nude mice. Tumour sections were stained with haematoxylin and eosin 
(row 1 = 40´ magnification), immunohistochemically for CD31 
(row 2 = 100´) and PCNA (row 3 = 100´); and immunofluorescently for
TUNEL (row 4 = 400´) and sequential CD31 (red) and TUNEL (green) 
(row 5 = 400´). (-)-epigallocatechin gallate (EGCG) treatment led to
decreases in number of tumour vessels (row 2) and tumour cell proliferation
(row 3) and an increase in endothelial cell apoptosis (row 5) relative to
treatment with (-)-epicatechin (EC) (column 1) EGCG inhibits tumour growth and VEGF expression 849
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The Erk-1 and Erk-2 pathway is also thought to be essential
in cellular growth and differentiation. Blockade of the Mek-Erk
pathway suppresses growth of colon tumours in vivo (Sebolt-
Leopold et al, 1999). Recently, Erk-1 and Erk-2 has been reported
to be an important signalling cascade that leads to overexpression
of VEGF mRNA (Jung et al, 1999; Milanini et al, 1998). We
previously showed that VEGF is up-regulated in serum-starved
HT29 cells through the activation of Erk-1 and Erk-2 (Jung et al,
1999). Milanini et al (1998) also found that maximal transcrip-
tional activation of VEGF in fibroblasts was Erk-dependent. The
EGCG-mediated inhibition of Erk-1 and -2 activation may be an
early cellular event that is partly responsible for the anticancer
effect of EGCG. 
The exact mechanism by which ECGC inhibits the activation of
Erk-1 and -2 in serum-starved cells is not known. One possible
explanation is that EGCG could inhibit kinases that are involved in
Erk-1 and -2 activation. EGCG is known to be a strong metal ion
chelator (Yang and Wang, 1993). Since some receptor kinases
depend on divalent cations for their activity (Mahadevan et al,
1995), EGCG could inhibit the activity of receptor kinases by
chelating the divalent cations. 
VEGF is a potent and unique angiogenic protein that has
specific mitogenic and chemotactic effects on vascular endothelial
cells. Studies from our laboratory and others suggest that VEGF is
the angiogenic factor that is most closely associated with induction
and maintenance of the neovasculature in human colon cancer
(Warren et al, 1995; Ellis et al, 1996; Takahashi et al, 1996). Our
present results show that treatment of mice with EGCG resulted in
marked inhibition of the growth, vascularity, and proliferation of
human tumour xenografts in nude mice. We also found that EGCG
induced significant endothelial cell apoptosis, a result that
supports our earlier contention that VEGF is an in vivo survival
factor for tumour endothelium (Shaheen et al, 1999). 
These findings suggest that down-regulation of VEGF by
EGCG may lead to endothelial cell apoptosis within tumours,
which could not only inhibit new blood vessel formation and
tumour growth but also could lead to tumour cell apoptosis. These
findings are supported by other recent reports that green tea could
inhibit tumour growth by suppressing blood vessel growth (Cao
and Cao, 1999; Swiercz et al, 1999). 
These studies have demonstrated that green tea, and more
specifically EGCG, can inhibit tumour growth in vivo, possibly by
inhibiting the formation of new blood vessels. These findings may
partially explain the antineoplastic effects associated with drinking
green tea. A complete knowledge of the molecular mechanism or
mechanisms involved with the anti-tumour efficacy of green tea
polyphenols may be useful in devising better strategies for cancer
therapy. 
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